NCI Best Practices for Biospecimen Resources
Ethical, Legal, and Policy Best Practices
Overview and Challenges

P. Pearl O’Rourke, M.D.
Partners HealthCare System
Boston, MA
Topics

- Custodianship
- Informed Consent
- Privacy Protections
- Access to Biospecimens and Data
- Intellectual Property
AGENDA

• Overview of the Best Practices
• Overview of the Challenges*
• Comments re: Discontinuation

* Not all under the control of NCI
Custodianship

- Ensure specimen and data integrity
  - Within bank and recipient researchers
- Plans for retention and disposition of specimens and data
  - At completion of research use
  - In the event of Resource closure/transfer
- Identification and management of conflict of interest
- Transparent and culturally sensitive policies
Informed Consent - 1

- Description of the bank operations
  - How data will be stored
  - How specimens can be accessed
  - Oversight of the bank
- Information about the risks and potential consequences of genetic research
- Ideally obtain consent prior to ‘procedure’
- Specify commercial use potential
Plans for release of aggregate and/or individual research results to individual, family, health care provider

Plans for longitudinal data collection

Plans for re-contact
  - If so, for what

Consider tiered consent

Arrangement for withdrawal from study

Be aware of pediatric issues
Privacy Protections

• Clear and transparent policies regarding how data will be held
  • Encrypted
  • Coded
• Consider a Certificate of Confidentiality
• Compliance with HIPAA
  • Privacy and Security
Access

- Transparent set of general principles
- Scientifically sound and appropriate research design
  - Agreement to publish
- Compliance with privacy and human subject protection regulations and statutes
- System of defined levels of access privileges for Resource staff
- Charges, if any, limited to reasonable costs
• Consistent with NIH Research Tools and NIH Data Sharing Policies
• Biospecimen resource staff not considered a priori inventors for inventions made with biospecimens
• Biospecimen resources have no right to future IP
• What does voluntary truly mean?
  • Consequences for not applying
  • Should all biospecimen resources be c/w the NCI best practices
• Logistic nightmare of dueling rules
  • Genome Wide Association Study (GWAS)
  • Local repositories
CHALLENGES: Custodianship

- To whom does the specimen belong?
- What is a gift?
- Expectations of donors
- The effect of court decisions
  - Very little case law – and what exists is state based
  - Courts have been particularly sensitive to the public policy implications of interfering with the biomedical research process
CHALLENGES: Privacy Protections

- HIPAA: collaboration between a variety of HIPAA entities and uncovered entities
- Future unspecified research uses
  - Disconnect between authorization (HIPAA) and informed consent (Common Rule)
- Possible overuse of Certificates of Confidentiality
  - Will their value be eroded?
CHALLENGES: Access & IP

- Access to specimens
  - Standardization of access rules
    - Especially in terms of scientific rigor
- Intellectual Property and Resource Sharing
  - Any exclusivity clause?
  - How does this compare to GWAS?
CHALLENGES: Informed Consent

- Timing of informed consent
- Who can obtain consent
- Pediatric consent
- Tiered consent
  - Logistics and understanding
- Discontinuation of participation*
C.2.2.9

“In the event that participation in the research study is discontinued, any remaining identifiable biospecimens and associated clinical data should be withdrawn from the biospecimen resource. However, samples and/or clinical data that have been transferred from the biospecimen resource to investigators and research data already generated from samples need not be withdrawn.”
C.2.2.9
“Instead if a biospecimen resource learns about the discontinuation of participation of a human subject, the NCI considers the biospecimen resource ethically obligated to inform investigators who received specimens from that individual.”
CHALLENGES: Discontinuation

- Investigators who receive identifiable specimens should withdraw that subject from the research

- Recipient investigators could:
  - Cease using identifiable specimens
  - Remove identifiers and continue to use*
  - Destroy identifiable specimens and data
Places unreasonable onus on investigators
• Expectation that recipient investigator withdraw specific specimens and data.
  • Does this mean cessation of further use?
  • Does this mean destruction of any research data created using these specimens?
**SUGGEST:** investigators be allowed to continue to use specimens and data already received

- Such plans should be described in the informed consent by stating that, withdrawal from participation means that:
  - Specimens and data will be withdrawn from the Biospecimen Resource
  - Specimens provided to recipient researchers will not be withdrawn. Recipient researchers will be able to continue research with these specimens
**CHALLENGES: Discontinuation**

- Removal of identifiers renders the specimen not a human subject
  - If the specimen was obtained for research purposes pursuant to informed consent
    - *If a person withdraws consent, seems that the consent covers both the specimen AND the data*
  - De-identification should only be permitted if specifically described in the initial consent
• Tissue Banking is an invaluable resource for biomedical research
• The logistics of tissue banking are daunting
• NCI deserves kudos for their leadership